论文部分内容阅读
目的 观察和研究拉米夫定联合香菇多糖治疗慢性乙型肝炎的近期疗效。方法 选择慢性乙型肝炎患者 3 2例用拉米夫定 (10 0mg/d)和香菇菌多糖 (10mg/d)治疗为观察组 ,3 0例单用拉米夫定 (10 0mg/d)治疗作为对照组 ,治疗 6个月 ,观察症状体征、肝功能、乙肝病毒复制指标。结果 血清HBV -DNA阴转率与对照组之间无显著差异 (87 5 %对 83 3 % ,χ2 =0 2 17,P >0 0 5 ) ,观察组HBeAg阴转率显著高于对照组 (5 6 3 %对 2 6 7% ,χ2 =5 5 65 ,P <0 0 5 ) ,ALT的复常率亦显著高于对照组 (78 1%对 5 3 3 % ,χ2 =4 2 49,P<0 0 5 ) ,未发生不良反应。结论 拉米夫定联合香菇多糖治疗慢性乙型肝炎的近期疗效肯定 ,较单用拉米夫定疗效有明显提高 ,安全性良好 ,值得进一步研究推广
Objective To observe and study the short-term curative effect of lamivudine and lentinan on chronic hepatitis B patients. Methods Thirty two patients with chronic hepatitis B were treated with lamivudine (10 mg / d) and fructus mushroom polysaccharide (10 mg / d) as observation group, 30 patients with lamivudine alone (100 mg / d) Treatment as a control group, treatment for 6 months, observed symptoms and signs, liver function, hepatitis B virus replication indicators. Results There was no significant difference between the negative rate of serum HBV-DNA and the control group (87.5% vs 83.3%, χ2 = 0.171, P> 0.05), and the negative conversion rate of HBeAg in the observation group was significantly higher than that of the control group 5 6 3% vs 27 6%, χ2 = 5 5 65, P 0 05). The normalization rate of ALT was also significantly higher than that of the control group (78 1% vs 533%, χ2 = 4249, P <0 0 5), no adverse reactions. Conclusion lamivudine combined with lentinan in the treatment of chronic hepatitis B, the short-term curative effect is better than the single use of lamivudine efficacy was significantly improved, good safety, it is worth further study to promote